Statement: There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case.
Primary_evidence: Adverse Events 1:   Total: 16/56 (28.57%)   Pancytopenia 0/56 (0.00%)   Pericarditis 0/56 (0.00%)   Abdominal pain 1/56 (1.79%)   Anal fissure 1/56 (1.79%)   Ascites 1/56 (1.79%)   Constipation 0/56 (0.00%)   Diarrhoea 1/56 (1.79%)   Nausea 0/56 (0.00%)   Oesophageal pain 0/56 (0.00%)   Vomiting 0/56 (0.00%)   Disease progression 2/56 (3.57%)   Infusion related reaction 1/56 (1.79%)   Pain 0/56 (0.00%) Adverse Events 2:   Total: 11/37 (29.73%)   Pancytopenia 1/37 (2.70%)   Pericarditis 1/37 (2.70%)   Abdominal pain 2/37 (5.41%)   Anal fissure 0/37 (0.00%)   Ascites 0/37 (0.00%)   Constipation 1/37 (2.70%)   Diarrhoea 1/37 (2.70%)   Nausea 2/37 (5.41%)   Oesophageal pain 1/37 (2.70%)   Vomiting 2/37 (5.41%)   Disease progression 2/37 (5.41%)   Infusion related reaction 0/37 (0.00%)   Pain 1/37 (2.70%)